Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis
Antibodies against mutated citrullinated vimentin (AMCV) represent a useful diagnostic marker with correlation to disease activity in patients with rheumatoid arthritis (RA). Since seropositivity for citrullinated autoantibodies was predictive for response to B-cell depleting therapy (BCDT) with rituximab (RTX), we investigated whether differences in antibody fine reactivity and immunoglobulin (Ig) isotype kinetics among AMCV-positive patients could provide additional information about outcome. A total of 50 AMCV IgG-positive RA patients (RTX responders (RRs) n = 37 and non-responders (NRRs) n... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Reihe/Periodikum: | Arthritis research & therapy |
Verlag/Hrsg.: |
London,
BioMed Central
|
Sprache: | Englisch |
ISSN: | 1478-6354 |
Weitere Identifikatoren: | doi: 10.1186/s13075-015-0717-z |
Permalink: | https://search.fid-benelux.de/Record/olc-benelux-1961018802 |
URL: | NULL NULL |
Datenquelle: | Online Contents Benelux; Originalkatalog |
Powered By: | Verbundzentrale des GBV (VZG) |
Link(s) : | http://dx.doi.org/10.1186/s13075-015-0717-z
http://dx.doi.org/10.1186/s13075-015-0717-z |